Document:

Exhibit 10.40

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (this “Agreement”) is made and entered into effective as of November 25, 2013, by and between Receptos, Inc. (the “Company”) and Christian Waage (“Executive”).  The Company and Executive are hereinafter collectively referred to as the “Parties.”

 

W I T N E S S E T H:

 

A.                                    The Company desires assurance of the association and services of Executive in order to retain Executive’s skills, abilities, background and knowledge, and is willing to engage Executive’s services on the terms and conditions set forth in this Agreement.

 

B.                                    Executive desires to be in the employ of the Company and is willing to accept such employment on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, for and in consideration of the employment by the Company, the compensation and other remuneration paid and to be paid by the Company and received and to be received by Executive for such employment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Executive, it is agreed by and between the Parties hereto as follows:

 

1.                                      Duties.  As the Company’s Senior Vice President and General Counsel, Executive will be responsible for the Company’s legal affairs, and Executive will perform such duties as are ordinary, customary and necessary in Executive’s role.  Executive will report directly to the Company’s Chief Executive Officer (the “CEO”) who will be primarily responsible for evaluating Executive’s performance.  The Company may change Executive’s duties, compensation, benefits and place of employment from time to time as it deems necessary.  In addition, during Executive’s employment with the Company, Executive shall devote Executive’s best efforts and Executive’s full business time, skill and attention to the performance of Executive’s duties on behalf of the Company.

 

2.                                      Salary and Bonus.  Executive will be compensated for full-time service (pro-rated for any part-time service) at a base rate of $295,000 per year, less all deductions and withholdings, to be paid in accordance with the Company’s standard payroll practices, as they may be changed from time to time.  In addition, Executive shall be eligible to receive an annual discretionary bonus with a target (the “Target Bonus”) of thirty percent (30%) of Executive’s base salary per 12-month period (pro-rated for any partial period of less than 12 months), based upon a determination by the CEO and the Company’s Board of Directors (the “Board”) of the achievement of objectives to be set from time to time by the Board.  The measurement period for this purpose will end on approximately December 31 of each year.  The annual discretionary bonus, if earned, will be paid as soon as practicable after it is determined that such bonus has been earned, but in no event will such bonus be paid after the later of (i) the fifteenth (15th) day of the third (3rd) month following the close of the Company’s taxable year in which the bonus is earned or (ii) March 15 following the calendar year in which the bonus is earned.  These bonuses are intended to be exempt (to the extent applicable) from the deduction limit of Section 162(m) of the Internal Revenue Code (the “Code”).  The Company may modify Executive’s compensation and benefits from time to time at its sole discretion.

 

 

3.                                      Other Benefits.  The Company will provide Executive with participation in Company-sponsored employee benefits programs on the same basis as such benefits are generally available to its executives, as determined from time to time by the Board.  The Company may, from time to time, change these benefits.

 

4.                                      Confidentiality Agreement.  One of the conditions of Executive’s employment with the Company is the maintenance of the confidentiality (and proprietary nature) of the Company’s proprietary and confidential information.  Executive agrees to execute and deliver the Company’s Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A, the terms and conditions of which are incorporated herein by reference.

 

5.                                      At-Will Employment.  Executive’s employment with Company is “at-will.”  This means that either Executive or the Company may terminate Executive’s employment at any time, with or without cause, and with or without notice.  Any contrary representations or agreements which may have been made to Executive are superseded by this Agreement.  The “at-will” nature of Executive’s employment described in this Agreement shall constitute the entire agreement between Executive and the Company concerning the nature and duration of Executive’s employment.  Though Executive’s duties, compensation, benefits and place of employment may change over time and Executive may be subject to incremental discipline that does not include a termination, none of these events change the agreement that Executive is an “at-will” employee.  In addition, the fact that the rate of Executive’s salary or other compensation is stated in units of years or months, and that Executive’s vacation and sick leave accrue annually or monthly, does not alter the at-will nature of the employment, and does not mean and should not be interpreted to mean that Executive is guaranteed employment to the end of any period of time or for any period of time.  The “at-will” term of Executive’s employment with the Company can only be changed in a writing signed by Executive and the Company.

 

6.                                      Severance Payment.  Without limiting the provisions of the foregoing Section 5, assuming Executive’s employment with the Company shall have been continuous from Executive’s start date through the occurrence of the applicable event and Executive executes and delivers, within twenty-one (21) days (or, to the extent required by law, forty-five (45) days) following the termination date, a general release of claims against the Company or persons affiliated with the Company (with any revocation periods having expired) substantially in the form as set forth on Exhibit B attached hereto (a “Release”), then:

 

a.                                      In the event of any Termination without Cause (as defined below) or any Constructive Termination (as defined below) which occurs during the period commencing one (1) month prior to a Change in Control (as defined below) and terminating twelve (12) months after such Change in Control (the “Change in Control Period”), Executive will be entitled to the following:

 

2

 

i.                              a lump sum payment (paid on the sixtieth (60th) day following such termination of employment) equal to the sum of (A) Executive’s then current base salary rate calculated for a period of twelve (12) months and (B) one (1) times the Target Bonus calculated for a period of twelve (12) months (i.e., no proration);

 

ii.                           if Executive elects to continue Executive’s health insurance coverage under COBRA, then the Company will reimburse Executive for the same portion of Executive’s monthly premiums over such twelve (12) month period under COBRA (or, if applicable, such lesser period as is available to Executive under COBRA) as the Company is then paying (relative to health insurance coverage) for active employees; and

 

iii.                        the vesting arrangements with respect to any equity-based compensation (e.g., any stock options and any shares of restricted stock) will thereupon accelerate such that Executive will be vested in full; provided, however, that (A) in the event that a Termination without Cause or a Constructive Termination occurs during the one (1) month prior to a Change in Control (i.e., the first month of a Change in Control Period), any equity-based compensation outstanding as of Executive’s termination shall not accelerate in connection with such termination but instead will remain outstanding and eligible to vest pursuant to this provision immediately prior to the consummation of such Change in Control (assuming the timely execution and non-revocation of a Release) and (B) in the event that a Termination without Cause or a Constructive Termination occurs prior to a Change in Control and such Change in Control is not consummated on or prior to the one (1) month anniversary of such termination, no vesting shall occur pursuant to this provision and any equity-based compensation outstanding as of Executive’s termination shall terminate in accordance with its terms; and

 

b.                                      In the event of any Termination without Cause or any Constructive Termination which occurs outside of a Change in Control Period, Executive will be entitled to the following:

 

i.                                          a lump sum payment (paid on the sixtieth (60th) day following such termination of employment) equal to Executive’s then current base salary rate calculated for a period of nine (9) months; and

 

ii.                                       if Executive elects to continue Executive’s health insurance coverage under COBRA, then the Company will reimburse Executive for the same portion of Executive’s monthly premiums over such nine (9) month period under COBRA as the Company is then paying (relative to health insurance coverage) for active employees.

 

The following definitions shall apply for purposes of this Section 6:

 

·                                          A “Change in Control” has the meaning set forth in the Company’s 2013 Stock Incentive Plan.

 

·                                          “Constructive Termination” means Executive’s election in a written notice to the Company to terminate any employment relationship where such notice is delivered within ninety (90) days after any of the following:  (i) a material reduction in Executive’s level of duties or responsibilities or the nature of Executive’s functions; (ii) a material reduction in Executive’s base salary or potential total cash compensation (consisting of base salary and target bonus); (iii) a relocation of Executive’s principal place of

 

3

 

employment by more than fifty (50) miles, if the new location is both (A) more than fifty (50) miles from Executive’s principal residence and (B) farther from Executive’s principal residence than Executive’s principal place of employment immediately before such relocation; or (iv) any material breach of Executive’s employment agreement by the Company; provided, that in all cases such action is not cured within thirty (30) days following written notice and, if the Company has not cured such action within the cure period, termination of employment occurs within thirty (30) days after the end of such cure period.

 

·                                          “Termination without Cause” means the termination by the Company of any employment relationship with Executive for any reason other than:  (i) commission by Executive of any act of fraud or embezzlement with regard to the Company or one or more of its parent or subsidiary corporations; (ii) any material, intentional and unauthorized use or disclosure of material confidential information or trade secrets of the Company or one or more of its parent or subsidiary corporations by Executive (other than in the good-faith performance of Executive’s duties); (iii) any other intentional misconduct by Executive with regard to the Company or one or more of its parent or subsidiary corporations (including severe absenteeism other than as a result of physical or mental incapacity) which adversely affects the business or affairs of the Company or one or more of its parent or subsidiary corporations in a material manner; or (iv) Executive’s failure to attempt in good faith to either perform duties consistent with Executive’s position with the Company or one or more of its parent or subsidiary corporations or to follow the reasonable requests of the Company’s Board, so long as Executive has been provided with an opportunity for a period of at least ten (10) business days following written notice to Executive to cure such failure; provided, however, that clause (iv) shall no longer apply following a Change in Control.

 

7.                                      Arbitration.  To aid in the rapid and economical resolution of any disputes that may arise in the course of the employment relationship, Executive and the Company agree that any and all disputes, claims, or demands in any way arising out of or relating to the terms of this Agreement, Executive’s employment relationship with the Company, or the termination of Executive’s employment relationship with the Company, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Diego, California, conducted before a single neutral arbitrator selected and administered in accordance with the commercial arbitration rules of the Judicial Arbitration and Mediation Services (JAMS).  By agreeing to this arbitration procedure, Executive and the Company waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding in any jurisdiction.  Executive will have the right to be represented by legal counsel at any arbitration proceeding, at Executive’s expense.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based; and (c) award to the prevailing party recovery of reasonable attorneys’ fees and costs, and determine which party shall be deemed the prevailing party and to what extent; provided, however, that if the dispute relates to the termination of Executive’s employment during a Change in Control Period, the Company shall pay Executive’s

 

4

 

reasonable attorneys’ fees and costs unless the arbitrator determines that Executive’s claims were made in bad faith or were frivolous.  The Company shall pay the arbitration fee unless, at Executive’s request, Executive elects to pay up to one-half of the fees.  Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm (including, without limitation, pending the conclusion of any arbitration).

 

8.                                      Code Section 409A.  The intent of the Parties is that payments and benefits under this Agreement and any equity-based compensation (e.g., any stock options and any shares of restricted stock) comply with, or be exempt from, Code Section 409A and, accordingly, to the maximum extent permitted, this Agreement and any equity-based compensation shall be interpreted to be in compliance therewith or exempt therefrom.  If Executive notifies the Company (with specificity as to the reason therefor) that Executive believes that any provision of this Agreement or any equity-based compensation (or of any award of compensation) would cause Executive to incur any additional tax or interest under Code Section 409A and the Company concurs with such belief or the Company independently makes such determination, the Company shall, after consulting with Executive, reform such provision to try to comply with Code Section 409A through good-faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A.  To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good-faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Code Section 409A.

 

a.                                      A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered “nonqualified deferred compensation” under Code Section 409A unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.”  If Executive is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment that is considered nonqualified deferred compensation under Code Section 409A payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of Executive’s “separation from service” and (B) the date of Executive’s death (the “Delay Period”).  Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section 8 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive in a lump sum with interest at the prime rate as published in The Wall Street Journal on the first business day following the end of the Delay Period, and any remaining payments and benefits due under this letter shall be paid or provided in accordance with the normal payment dates specified for them herein.

 

5

 

b.                                      With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Executive’s taxable year following the taxable year in which the expense occurred.

 

c.                                       For purposes of Code Section 409A, Executive’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.  In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement that is considered nonqualified deferred compensation.

 

9.                                      Excess Parachute Payments; Limitations on Payments.

 

a.                                      In the event that, on or prior to March 31, 2015, a definitive agreement is executed by the Company pursuant to which a Change in Control (as defined in Section 6) is expected to occur (a “Definitive Agreement”), this Section 9(a) shall apply to such Change in Control.

 

i.                                          In the event it shall be determined that any payment or distribution made to Executive in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) (the “Payment”) would be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”) then, subject to Section 9(a)(iv) hereof, Executive shall be entitled to receive an additional payment (a “Gross-Up Payment”) in an amount such that, after payment by Executive of all taxes (including, without limitation, any income and employment taxes and Excise Tax) imposed upon such Gross-Up Payment, Executive retains an amount of such Gross-Up Payment equal to the Excise Tax imposed upon the Company Payments (as defined below) to Executive; provided, however, that (A) in no event shall such Gross-Up Payment exceed the Applicable Limit (as defined below) and (B) except in the instance of a Termination without Cause or a Constructive Termination, the Company’s obligation to make a Gross-Up Payment under this Section 9(a) shall be conditioned upon Executive’s continuation of employment through the applicable Change in Control.

 

A.                                    “Applicable Limit” for a Change in Control shall mean the lesser of the following:  (1) the Relative Portion (as defined below) of (x) if the Definitive Agreement for such Change in Control is entered into on or prior to July 31, 2014, two percent (2%) of the Transaction Value (as defined below) of such Change in Control or (y) if the Definitive Agreement for such Change in Control is entered into following July 31, 2014 (but no later than March 31, 2015), one and one-half percent (1.5%) of the Transaction Value of such Change in Control; (2) if the Definitive Agreement for such Change in Control is entered into on or prior to July 31, 2014, one percent (1%) of the Transaction Value of such Change in Control, or if the Definitive Agreement for such Change in Control is entered into following July 31, 2014 (but no later than March 31, 2015), three-quarters of one percent (0.75%) of the Transaction Value of such Change in Control; and (3) any limit agreed to in writing by the Company and Executive.

 

6

 

B.                                    “Company Payments” shall mean Payments (other than a Gross-Up Payment) provided under a plan, program, agreement or arrangement with the Company or its subsidiaries to the extent in effect as of immediately prior to the consummation of the applicable Change in Control.  For the avoidance of doubt, Company Payments shall not include Payments provided under a plan, program, agreement or arrangement to which none of the Company and its subsidiaries is a party.

 

C.                                    “Participating Executives” shall mean the Company’s “disqualified individuals” (within the meaning of Section 280G of the Code), that are parties to an effective employment agreement with the Company (including Executive) providing for the same or similar rights and/or benefits as are set forth in this Section 9(a).  Notwithstanding any provision herein to the contrary, the Company may at any time and from time to time prior to a Change in Control increase the number of Participating Executives.

 

D.                                    “Relative Portion” shall mean a fraction, the numerator of which is the potential Excise Tax that may be imposed on all potential Company Payments that may be made to Executive with respect to a Change in Control, and the denominator of which is the aggregate potential Excise Tax that may be imposed on all potential Company Payments to all Participating Executives (including Executive) with respect to such Change in Control, in each case determined no later than the date of the consummation of such Change in Control by the Board in place as of immediately prior to the consummation of such Change in Control.

 

E.                                     “Transaction Value” shall mean the present value, as of the consummation of a Change in Control at issue, of the fair market value (including, without limitation, as risk-adjusted) of all payments or other distributions to the holders of the Company’s equity securities pursuant to such Change in Control, as determined no later than the date of the consummation of such Change in Control by the Board in place as of immediately prior to the consummation of such Change in Control.

 

ii.                                       All determinations required to be made under this 9(a), including whether and when a Gross-Up Payment is required, the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by Ernst & Young or such accounting or consulting firm with particular expertise regarding excise taxes under Section 4999 of the Code selected by the Board in good faith prior to the applicable Change in Control (the “Accounting Firm”).  The Accounting Firm shall provide detailed supporting calculations both to the Company and to Executive within fifteen (15) business days of the receipt of notice that there has been a Company Payment to Executive that may be or become subject to the Excise Tax, or such earlier time as is requested by Executive or the Company.  All fees and expenses of the Accounting Firm shall be borne solely by the Company.  Any Gross-Up Payment, as determined pursuant to this Section 9(a)(ii), shall be paid by the Company to Executive within ten (10) days of the receipt of the Accounting Firm’s determination (and in any event, no later than the end of Executive’s taxable year next following Executive’s taxable year in which Executive remits the related taxes).  Any determination by the Accounting Firm shall be binding upon the Company and Executive.

 

7

 

iii.                                    As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder it is possible that Gross-Up Payments will not have been made by the Company that should have been made to Executive (the “Underpayment”), consistent with the calculations required to be made hereunder.  In the event that it is determined by a court of competent jurisdiction or by the Accounting Firm upon request of Executive or the Company that an Underpayment has occurred, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to Executive or for Executive’s benefit (subject to Section 9(a)(v) hereof), together with an additional payment (the “Time Value Payment”) in an amount equal to the product obtained by multiplying the Underpayment times the applicable annual federal rate (as determined in and under Section 1274(d) of the Code) times a fraction the numerator of which is the number of days elapsed from the date of the Underpayment through the date of such payment and the denominator of which is 365; provided, that in no event shall the sum of the Gross-Up Payment previously paid to Executive and the Underpayment exceed the sum of the Applicable Limit plus the Time Value Payment.  If, after Executive’s receipt of (or a payment on behalf of Executive of) a Gross-Up Payment, it is established, pursuant to a final determination of a court or an Internal Revenue Service (“IRS”) proceeding that has been finally and conclusively resolved, that Gross-Up Payments have been made by the Company that should not have been made (in each case, the “Excess Payment”), Executive shall (subject to the Company’s complying with the requirements of this Section 9(a)(iii), if applicable) promptly pay to the Company the Excess Payment together with an additional payment in an amount equal to the product obtained by multiplying the Excess Payment times the applicable annual federal rate (as determined in and under Section 1274(d) of the Code) times a fraction the numerator of which is the number of days elapsed from the date of Executive’s receipt of such Excess Payment through the date of such refund and the denominator of which is 365.

 

iv.                                   Notwithstanding anything herein to the contrary, if any Gross-Up Payment(s) become payable, such Gross-Up Payment(s) shall be paid to Executive no later than December 31 of the year following the year in which the underlying taxes are remitted to the appropriate taxing authority.

 

v.                                      For purposes of determining the amount of the Excise Tax, the Company Payments made to Executive shall be deemed to have been made prior to any other Payment made to Executive.  For purposes of determining the amount of any Gross-Up Payment, Executive shall be deemed to pay federal income tax at the highest marginal rate of federal income taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rate of taxation in the state and locality of Executive’s residence in the calendar year in which the Gross-Up Payment is to be made, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.

 

vi.                                   If any Payment (including without limitation any Company Payment) or portion thereof would constitute a “parachute payment” within the meaning of Section 280G of the Code and (A) but for this sentence, would be subject to the Excise Tax and (B) Executive’s liability for such Excise Tax would not be wholly satisfied by the Gross-Up Payment payable in accordance with Section 9(a) hereof (all such Payments (or portions thereof) being hereinafter referred to as the “Total Payments”), then such Total Payments shall be whichever of the following amounts, after taking into account all applicable federal, state and

 

8

 

local employment taxes, income taxes, the Excise Tax and the Gross-Up Payment (if applicable), that results in Executive’s receipt, on an after-tax basis, of the greater amount:  (x) the net amount of the Total Payments that would result in no portion of the Total Payments being subject to the Excise Tax; or (y) the net amount of the Total Payments without reduction (notwithstanding that all or some portion of the Total Payments may be subject to the Excise Tax).  If a reduction in the Total Payments is necessary so that the Total Payments equal the amount described in subsection (x) above, reduction shall occur in the following order: (1) the cancellation of acceleration of vesting of any equity awards for which the exercise price exceeds the then fair market value of the underlying equity (the “GAP”) that have a ninety (90) day or less exercise period, starting with such equity awards with the largest amount of GAP, (2) reduction of cash payments (in reverse order of the date otherwise due), (3) reduction of employee benefits (in reverse order of the date otherwise due), and (4) the cancellation of vesting of any equity awards not covered in clause (1) above, provided, that such cancellation will first apply to equity awards that are “fully valued” under Section 280G of the Code (including those subject to present value adjustments) and thereafter, to equity awards valued on an acceleration of vesting basis, provided, further, within each category, the cancellation shall be in a manner as providing Executive with the highest net amount; provided, that to the extent permitted by Code Section 409A and Sections 280G and 4999 of the Code, if a different reduction procedure would be permitted without violating Code Section 409A or losing the benefit of the reduction under Sections 280G and 4999 of the Code, Executive may designate a different order of reduction.  For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no portion of the Total Payments the receipt or enjoyment of which Executive shall have waived at such time and in such manner as not to constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken into account; (ii) no portion of the Total Payments shall be taken into account which, in the written opinion of the Accounting Firm, does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments shall be taken into account which, in the opinion of the Accounting Firm, constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount” (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation; and (iii) the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Accounting Firm in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

 

b.                                      In the event that a Definitive Agreement is executed by the Company after March 31, 2015, Section 9(a)(vi) shall apply to such Change in Control (without regard to Sections 9(a)(i) - 9(a)(v), which shall not apply).

 

10.                               Miscellaneous.  Executive agrees to abide by all applicable laws and regulations and all Company policies and procedures as they are established.  Violation of such laws, regulations, policies, procedures or the Proprietary Information and Inventions Agreement may lead to immediate termination of employment.  The terms of this Agreement and Executive’s employment with the Company shall be governed in all aspects by the laws of the State of California.  This Agreement may be executed in more than one counterpart, and signatures transmitted via facsimile or PDF shall be deemed equivalent to originals.

 

9

 

11.                               Integrated Agreement.  This Agreement supersedes any prior agreements, representations or promises of any kind, whether written, oral, express or implied between the Parties with respect to the subject matters herein.  Likewise, the terms of this Agreement and the Proprietary Information and Inventions Agreement incorporated herein by reference shall constitute the full, complete and exclusive agreement between Executive and the Company with respect to the subject matters herein.  This Agreement may only be changed by a writing, signed by Executive and an authorized representative of the Company.

 

12.                               Withholding.  Any payments or other compensation provided to Executive or for Executive’s benefit will be subject to (and thus reduced by) all applicable deductions and withholdings.

 

13.                               Severability.  If any term herein is held to be invalid, void or unenforceable, the remainder of the terms herein shall remain in full force and effect and shall in no way be affected, and the Parties shall use their best efforts to find an alternative way to achieve the same result.

 

14.                               Successors.

 

a.                                      This Agreement is personal to Executive and, without the prior written consent of the Company, shall not be assignable by Executive otherwise than by will or the laws of descent and distribution.  This Agreement shall inure to the benefit of and be enforceable by Executive’s legal representatives.

 

b.                                      This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.  The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.  As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.

 

15.                               Amendment.  No amendment or other modification of this Agreement shall be effective unless made in writing and signed by the parties hereto.

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.

 

	
THE COMPANY:
    	
EXECUTIVE:
    
	
 
    	
 
    
	
RECEPTOS, INC.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Faheem Hasnain
    	
 
    	
By:
    	
/s/ Christian Waage
    
	
 
    	
Faheem Hasnain
    	
 
    	
Christian Waage
    
	
 
    	
President and Chief Executive Officer
    	
 
    
					

 

10

 

 

EXHIBIT A

 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

 

Receptos, Inc.

10835 Road to the Cure, #205

San Diego, CA 92121

 

Ladies and Gentlemen:

 

I recognize that Receptos, Inc., a Delaware corporation (“Receptos”), possesses a body of existing technology and intellectual property rights and is engaged in a continuous program of research, development and production with respect to its business (present and future).

 

I understand that:

 

A.                                   As part of my employment by Receptos (with the term “employment”, as used herein, to include any consulting relationship as well as any service as a member of the Board of Directors), I am expected to make new contributions and inventions of value to Receptos.

 

B.                                    My employment creates a relationship of confidence and trust between me and Receptos and that my position places me in a unique position of access to the proprietary technology, trade secrets and research, development and business information:

 

(1)                         applicable to the business of Receptos; or

 

(2)                         applicable to the business of any client, partner or customer of Receptos,

 

which may be made known to me by Receptos or by any client, partner or customer of Receptos, or learned by me during the period of my employment.

 

C.                                   Receptos possesses and will continue to possess information that has been or will be created, discovered or developed, or has or will otherwise become known to Receptos (including, without limitation, information created, discovered, developed or made known by or to me during the period of or arising out of my employment by Receptos), and/or in which property rights have been or will be assigned or otherwise conveyed to Receptos, which information has commercial value in the business in which Receptos is engaged. All of the aforementioned information is hereinafter called “Confidential Information.”  By way of illustration, but not limitation, Confidential Information includes all data, compilations, blueprints, plans, audio and/or video recordings and/or devices, information on computer disks, software, tapes, printouts and other printed, typewritten or handwritten documents, specifications, strategies, systems, schemas, methods, business and marketing development plans, customer, employee and supplier lists, budgets and unpublished financial statements, licenses and license agreements, research projections, processes, techniques, designs, sequences, components, programs, technology, ideas, know-how, improvements, inventions (whether or not patentable or copyrightable), information about operations and maintenance, trade secrets, formulae, models, patent disclosures, information regarding the skills and compensation of other employees of Receptos and other information concerning the actual or anticipated business, research or development of Receptos or its actual or

 

 

potential customers, suppliers or partners or which is or has been generated or received in confidence by or for Receptos by or from any person; and all tangible and intangible embodiments thereof of any kind whatsoever including, where appropriate and without limitation, all compositions, machinery, apparatus, records, reports, drawings, copyright applications, patent applications, documents, samples, prototypes, models, products and the like.

 

In consideration of my employment or continued employment, as the case may be, and the compensation received by me from Receptos from time to time, I hereby agree as follows:

 

1.                                      All Confidential Information shall be the sole property of Receptos and its assigns, and Receptos and its assigns shall be the sole owner of all trade secrets, patents, copyrights and other rights in connection therewith.  I hereby assign to Receptos any rights I may have or acquire in all Confidential Information. At all times during my employment by Receptos and at all times after termination of my employment by me or Receptos for any reason (“Termination”), I will hold in confidence and trust all Confidential Information, and I will not disclose, sell, use, lecture upon or publish any Confidential Information or anything relating to it without the prior written consent of Receptos, except as may be necessary in the ordinary course of performing my duties as an employee of Receptos.

 

2.                                      Without limiting the terms of my employment with Receptos, I agree that during the period of my employment by Receptos I will not engage in any employment or activity in any business that is directly or indirectly competitive with Receptos or would otherwise conflict with my employment by Receptos.

 

3.                                      All documents, data, records, apparatus, equipment, sequences, components, programs and other physical property, whether or not pertaining to Confidential Information, furnished to me by Receptos or produced by myself or others in connection with my employment shall be and remain the sole property of Receptos and shall be remain promptly to Receptos as and when requested by Receptos.  Even should Receptos not so request, I shall return and deliver all such property upon Termination and I will not take with me any such property, any reproduction of such property or any materials or products derived from such property.  I further agree that any property situated on Receptos’ premises and owned by Receptos, including disks and other storage media,  filing cabinets or other work areas, is subject to inspection by Receptos personnel at any time with or without notice.

 

4.                                      I shall promptly disclose any outside activities or interests, including any ownership or participation in the development of Prior Inventions (as defined in Section 8 below), that conflict or may conflict with the interests of Receptos.  I understand that I am required to make such disclosures promptly if the activity or interest is related, either directly or indirectly, to (i) an area of research, development or service of Receptos, (ii) a product candidate, product or product line of Receptos, (iii) a manufacturing, development or research methodology or process of Receptos or (iv) any activity that I may be involved with on behalf of Receptos.

 

5.                                      I shall promptly disclose to Receptos, or any persons designated by it, all improvements, inventions, formulae, processes, programs, techniques, know-how, data and the like, whether or not patentable or copyrightable, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with Receptos which are related to the business of Receptos, or result from tasks assigned to me by Receptos, or result from use of premises owned, leased or contracted for by Receptos (all said improvements, inventions, formulae, processes, techniques, know-how, data and the like shall be collectively hereinafter called “Inventions”).  Such disclosure shall continue for one year after Termination with respect to anything that would be an Invention if made, conceived, reduced to practice or learned prior to Termination.

 

6.                                      I agree to keep and maintain adequate and current records (in the form of notes, sketches, documentation, drawings and in any other form that may be required by Receptos) of all Confidential Information developed by me and all Inventions made by me during the period of my employment at Receptos, which records shall be made available to and remain the sole property of Receptos at all times.

 

 

7.                                      I agree that all Inventions shall be the sole property of Receptos and its assigns, and Receptos and its assigns shall be the sole owner of all trade secrets, patents, copyrights and other rights in connection therewith and all Confidential Information with respect thereto.  I hereby assign to Receptos any and all rights I may have or acquire in all Inventions, including all rights that may be known as or referred to as “moral rights.” I further agree as to all Inventions to assist Receptos in every proper way (but at Receptos’ expense) to obtain and from time to time enforce patents and copyrights on Inventions in any and all countries, and to that end I will execute all documents for use in applying for and obtaining such patents and copyrights thereon and enforcing the same, as Receptos may desire, together with any assignments thereof to Receptos or persons designated by it.  My obligation to assist Receptos in obtaining and enforcing patents and copyrights for the Inventions in any and all countries shall continue beyond Termination, but Receptos shall compensate me at a reasonable rate after Termination for time actually spent by me at Receptos’ request on such assistance. In the event that Receptos is unable for any reason whatsoever to secure my signature to any lawful and necessary document required to apply for or execute any patent or copyright application with respect to Inventions (including renewals, extension, continuations, divisions, continuations in part or preservation of rights in respect thereof), I hereby irrevocably designate and appoint Receptos and its duly authorized officers and agents, as my agents and attorneys-in-fact to act for and in my behalf and instead of me, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents or copyrights thereon with the same legal force and effect as if executed by me.

 

8.                                      As a matter of record I have identified on Appendix 1 hereto a complete list of all inventions or improvements relevant to the subject matter of my employment by Receptos which have been made or conceived or first reduced to practice by me alone or jointly with others prior to my employment by Receptos (“Prior Inventions”) which I desire to remove from the operation of this Agreement. If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Invention on Appendix 1 but am only to disclose a cursory name for each such Prior Invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such Prior Inventions has not been made for that reason.  I represent that my list of Prior Inventions is complete.  If no such list of Prior Inventions is identified, I represent that I have made no such Prior Inventions at the time of the commencement of my employment by Receptos.  Notwithstanding the foregoing, and without limiting the other provisions of this Agreement, I agree that (i) any improvements or new inventions to the item(s) so identified on such list (if any) shall be treated as Inventions for purposes of this Agreement if the provisions of Section 5 above are otherwise applicable and (ii) if, in the course of my employment with Receptos, I incorporate a Prior Invention into an Receptos product, process, application, machine or invention, Receptos is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual,  worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Receptos product, process, application, machine or invention without Receptos’ prior written consent.

 

9.                                      I represent that my performance of all the terms of this Agreement and that my employment by Receptos does not and will not breach or constitute an event of default under any agreement (i) obligating me to keep in confidence proprietary information acquired by me in confidence or in trust prior to, or at any point throughout, my employment by Receptos, (ii) obligating me to assign to or protect for the benefit of any third party any proprietary information or any improvement, invention, formulae, process, program, technique, know-how or data or (iii) that is designed in any way to limit my employment or activity in any business in which I may compete, directly or indirectly, with any other business, or which might by application have such an effect. I have not entered into, and I agree that I will not enter into, any agreement (either written or oral) in conflict herewith.

 

 

10.                               I understand, acknowledge and agree that, as part of the consideration for my employment or continued employment by Receptos, I have not brought and will not bring with me to Receptos or use in the performance of my responsibilities at or for Receptos any equipment, supplies, facilities, trade secrets or other proprietary information of any former employer which are not generally available to the public, unless I have obtained (and provide herewith to Receptos a copy of) written authorization for their possession and use.

 

11.                               I also understand that, during the course of my employment by Receptos, I am not to breach any obligation of confidentiality that I have to others, and I agree that I shall fulfill all such obligations during my employment by Receptos. A copy of any document reflecting any such obligation, or a description thereof if no document is available, is provided herewith to Receptos.

 

12.                               I agree that during the term of my employment with Receptos and for a period of twelve (12) months after Termination, I will not directly or indirectly: (i) induce or attempt to induce any employee or consultant of Receptos to leave the employ of Receptos or to otherwise end such employee’s or consultant’s relationships with Receptos or (ii) other than on behalf of Receptos, induce or attempt to induce any other person to terminate a relationship with Receptos.

 

13.                               After Termination, I hereby consent to the notification of my new employer (if any) of my rights and obligations under this Agreement.

 

14.                               I acknowledge that, due to the uniqueness of my relationship with Receptos, Receptos would not have an adequate remedy at law for money damages in the event that this Agreement is not fully performed in accordance with its terms.  I agree that in addition to any other rights and remedies available to Receptos for any breach by me of my obligations hereunder, Receptos shall be entitled to enforcement of my obligations hereunder by court injunction (without the posting of a bond or other security), specific performance or other appropriate equitable relief.

 

15.                               If any one or more of the provisions of this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.  If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

 

16.                               If applicable, this Agreement does not apply to inventions which quality fully for protection under Section 2870 of the California Labor Code (which, if applicable, could apply to ideas or inventions for which no equipment, supplies, facility or trade secret information of Receptos were used and which were developed entirely on my own time, and (i) which do not relate at the time of conception or reduction to practice of the invention (a) to the actual business of Receptos, or (b) to Receptos’ actual or demonstrably anticipated research or development, or (ii) which do not result from any work performed by me for Receptos). Notwithstanding the foregoing, I shall disclose in confidence to Receptos any invention in order to permit Receptos to make a determination as to compliance by me with the terms and conditions of this Agreement.

 

17.                               This Agreement shall be effective as of the first day of my employment by Receptos and shall survive Termination.  The term “employment”  and the term or duration of my employment, as used herein and for purposes of this Agreement, shall include, without limitation, any consulting relationship or service pursuant to a directorship between myself and Receptos (including, if applicable, any such relationship which may follow the termination of my status as an employee of Receptos or which may precede my status as an employee of Receptos).  Accordingly, notwithstanding any other provision of this Agreement to the contrary (and without limitation), a “Termination”  shall not be deemed to have occurred if a consulting relationship or directorship persists following the termination of my status as an employee of Receptos (if applicable).

 

 

18.                                    The term Receptos, as used herein, shall include any subsidiary or affiliate of Receptos.

 

19.                                    This Agreement shall be binding upon me, my heirs, executors, assigns and administrators and shall inure to the benefit of Receptos, its successors and assigns.

 

20.                                    This Agreement shall be governed by and construed in accordance with the internal laws of the State of California, without regard to the conflicts of law principles thereof.

 

 

I have read this Agreement carefully and understand its terms. The list of Prior Inventions attached on Appendix 1 is complete.

 

Dated:  November 25, 2013

 

 

	
Signature:
    	
/s/ Christian Waage
    	
 
    

 

Accepted and Agreed to

November 25, 2013

 

 

	
RECEPTOS, INC.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Graham Cooper
    	
 
    
	
Name:
    	
Graham   Cooper
    	
 
    
	
Its:
    	
Chief Financial Officer
    	
 
    

 

 

 

Appendix 1

 

Prior Inventions

 

(a)                                 Prior Inventions.  Except as set forth in part (b)  below, the following is a complete list of all Prior Inventions (as defined in Section 8 of the Proprietary Information and Inventions Agreement to which this Exhibit is attached) relevant to the present business of Receptos:

 

x                                  None.

 

o                                    See below.

 

 

o                                    Additional sheets attached.

 

(b)                                 Confidential Prior Inventions. Due to a prior confidentiality agreement, I cannot complete the disclosure with respect to the inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies):

 

	
 
    	
 
    	
Invention or Improvement
    	
 
    	
Party(ies)
    	
 
    	
Relationship
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
2.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
3.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

o  Additional Sheets Attached.

 

 

Exhibit B

 

(General Release of Claims)

 

NOTE:  This Agreement will not become effective or enforceable (and none of the consideration set forth in Section 1 below will be paid or recognized) until the seven (7) day revocation period referenced in Section 13 below has expired.

 

RELEASE

 

This Release (“Agreement”) is entered into effective [                         , 20    ] by and between Christian Waage (“Executive”) and Receptos, Inc., a Delaware corporation (“Receptos”), with reference to the following facts:

 

A.                                    Executive’s employment relationship with Receptos terminated effective [                   , 20    ] (the “Termination Date”).

 

B.                                    Executive [has been paid in full for]/[is entitled to receive] all accrued wages and accrued and unused vacation through the Termination Date.  [Executive has also been reimbursed by Receptos for all expenses incurred in connection with Executive’s employment relationship with Receptos through the Termination Date.]

 

NOW, THEREFORE, the parties hereby agree as follows:

 

1.                                      Severance Consideration.  In consideration of the covenants and promises contained in this Agreement, and as full and final compensation to Executive for all services as an employee of Receptos, Executive shall receive from Receptos (less appropriate deductions and withholdings) the severance payments set forth in Section 6 of Executive’s Employment Agreement dated November 25, 2013 (as amended to date) (the “Employment Agreement”).

 

2.                                      Release.  In consideration of the above-described consideration, Executive does hereby unconditionally, irrevocably and absolutely release and discharge Receptos, all related holding, parent or subsidiary corporations, and their affiliates, directors, officers, employees, agents, attorneys, stockholders, insurers, successors and/or assigns (collectively, the “Released Parties”), from any and all losses, liabilities, claims, demands, causes of action, or suits of any type, whether in law and/or in equity, known or unknown, related directly or indirectly or in any way connected with any transactions, affairs or occurrences between Executive, on the one hand, and any Released Party(ies), on the other hand, to date, with respect to Receptos and its holding, parent or subsidiary corporations (including, but not limited to, Executive’s employment with Receptos and the termination of said employment).  This release shall include but not be limited to a release of claims arising under any state or federal statute or common law regulating or affecting employment, including Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Equal Pay Act, the Fair Labor Standards Act, the California Labor Code, the California Fair Employment and Housing Act, and any other statutory or common law provision relating to or affecting Executive’s employment by Receptos, including any federal or state statutory provision covering any age discrimination in any form by Receptos against Executive.  This provision is intended to constitute a general release of all of Executive’s

 

1

 

presently existing claims against Receptos and its directors, officers and employees, as well as any other Released Parties, to the maximum extent permitted by law.  This release, however, shall not affect or bar any claims that Executive has or may have for the following:  (i) reimbursement of expenses under California Labor Code § 2802; (ii) workers compensation benefits; (iii) claims arising under section 7 of the National Labor Relations Act, as amended; (iv) California unemployment insurance benefits; (v) any other claim or cause of action that, by virtue of statute, public policy or otherwise, may not be released by an agreement knowingly and voluntarily entered into by the parties; (vi) any indemnification from (or insurance coverage through) Receptos in Executive’s capacity as a director or officer of Receptos or any entity where Executive served as an officer, director or other fiduciary at the request of Receptos; [(vii) any right of Executive to receive a Gross-Up Payment (as defined in, and pursuant to the terms of, Section 9 of the Employment Agreement);] and [(viii) vested rights under the following benefit plans: {      if any      }].  Notwithstanding any provision of this Agreement to the contrary, Executive does not waive any right or release any claim against Receptos which claim or right arises from Receptos failing to perform its undertakings as set forth in this Agreement.

 

3.                                      Claims.  Executive represents that Executive has not filed any complaints, claims, or actions against Receptos with any court or administrative agency.  If any agency or court has or assumes jurisdiction of any complaint, claim, or action against Receptos on behalf of Executive, Executive will request that agency or court to withdraw from or dismiss the matter with prejudice.  Executive also waives and will remit to Receptos any monetary recovery from any such proceeding. Executive further represents that Executive has reported to Receptos any and all known work-related injuries that Executive has suffered or sustained during Executive’s employment with Receptos.

 

4.                                      Unknown Claims.  Except as provided in Section 2 above, Executive understands and agrees that this release extends to all claims of every nature, known or unknown, suspected or unsuspected, past or present, and that any and all rights granted to Executive under Section 1542 of the California Civil Code or any analogous federal law or regulation are hereby expressly waived.  Said Section 1542 of the California Civil Code reads as follows:

 

“A general release does not extend to claims which the creditor does not know of or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.”

 

5.                                      Effect on Previous Agreements.  Except as provided in Section 2 above, this Agreement is intended to resolve any and all issues between Receptos and Executive, including, without limitation, any and all claims for wages, severance pay, compensation, stock options, stock grants, benefits, or other aspects of the employment relationship between Receptos and Executive.  This Agreement shall supersede and extinguish all prior employment agreements, express or implied, verbal or written, between Receptos and Executive; provided, however, that this Agreement shall have no effect on any of the following agreements previously executed by Executive:  (i) any proprietary information and invention agreements (or similar arrangements); (ii) any confidentiality agreements; and [(iii) the following agreements: {      if any      }].  Without limiting the foregoing, this Agreement shall also not in any way supersede or affect any obligation of Executive, contractual or otherwise, with respect to the disclosure, use or protection

 

2

 

of any proprietary or confidential information of Receptos, including any trade secrets, or with respect to the disclosure and assignment of inventions made or conceived by Executive during Executive’s employment.  All previous written agreements and obligations imposed by any contract relating to the intellectual property of Receptos or any of its subsidiary or affiliated entities shall remain in full force and effect and survive the execution of this Agreement.

 

6.                                      Binding Effect.  Executive further declares and represents that no promise, inducement or agreement not expressed herein has been made to Executive and that this Agreement contains the entire agreement between the parties relating to the subject matter hereof.

 

7.                                      Successors.  Receptos and Executive understand and expressly agree that this Agreement shall bind and benefit the heirs, partners, successors, employees, directors, stockholders, officers, attorneys, affiliates, predecessors, representatives and assigns of Receptos and Executive.

 

8.                                      Confidentiality.  Executive agrees not to disclose or publicize the existence of this Agreement or the terms hereof to any other party, except as may be necessary to enforce this Agreement or as may be required by law.  This provision shall not preclude Executive from disclosing, in confidence, the terms of this Agreement to (i) Executive’s legal or financial advisors, (ii) Executive’s spouse, or (iii) the appropriate Receptos personnel with responsibility for the performance by Receptos contemplated hereby (including, without limitation, effecting the severance payments set forth in Section 6 of Executive’s Employment Agreement dated November 25, 2013 (as amended to date)).

 

9.                                      Interpretation.  The validity, interpretation, and performance of this Agreement shall be construed and interpreted according to the laws of the State of California.  This Agreement shall not be interpreted for or against either party hereto on the ground that such party drafted or caused this Agreement to be drafted.  If any provision of this Agreement, or part thereof, is held invalid, void or voidable as against the public policy or otherwise, the invalidity shall not affect other provisions, or parts thereof, which may be given effect without the invalid provision or part.  To this extent, the provisions, and parts thereof, of this Agreement are declared to be severable.

 

10.                               Resolution of Employment Related Disputes.  Except as prohibited by law, Executive and Receptos agree that any and all disputes, claims, or demands in any way arising out of or relating to the terms of this Agreement, Executive’s employment relationship with Receptos, or the termination of Executive’s employment relationship with Receptos, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Diego, California, conducted before a single neutral arbitrator selected and administered in accordance with the commercial arbitration rules of the Judicial Arbitration and Mediation Services (JAMS).  By agreeing to this arbitration procedure, Executive and Receptos waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding in any jurisdiction.  Executive will have the right to be represented by legal counsel at any arbitration proceeding, at Executive’s expense.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the

 

3

 

arbitrator’s essential findings and conclusions on which the award is based; and (c) award to the prevailing party recovery of reasonable attorneys’ fees and costs, and determine which party shall be deemed the prevailing party and to what extent.  Receptos shall pay the arbitration fee unless, at Executive’s request, Executive elects to pay up to one-half of the fees.  Nothing in this Agreement is intended to prevent either Executive or Receptos from obtaining injunctive relief in court to prevent irreparable harm (including, without limitation, pending the conclusion of any arbitration).  This arbitration provision shall supersede any and all prior agreements between Receptos and Executive on the subject of arbitration of employment-related claims.

 

11.                               Return of Property.  Executive represents and warrants that Executive has returned to and/or left with Receptos all property and data that belongs to Receptos, including but not limited to Receptos’ computers, PDAs, blackberries, cell phones, credit cards, memoranda, documents, records, manuals, computer programs, discs, data, CDs, flash drives, email, and all other property and information pertaining to the business of Receptos (including, without limitation, the duties Executive performed for Receptos).  Notwithstanding the foregoing, Executive may retain Executive’s rolodex and similar address books provided that such items only include contact information.  Executive acknowledges that, as of the Termination Date, Executive’s authority to act on behalf of Receptos ended.

 

12.                               Admissions.  It is understood that this Agreement is not an admission of any liability whatsoever by either Receptos or Executive.

 

13.                               Older Workers Benefit Protection Act Acknowledgements.  Executive acknowledges and agrees that the consideration set forth in Section 1 above constitutes consideration beyond that which, but for the mutual covenants set forth in this Agreement, Receptos would be obligated to provide, or Executive otherwise would be entitled to receive.  Executive acknowledges that Executive has twenty-one (21) days after actual receipt of this Agreement in which to consider and execute this Agreement.  Changes to this Agreement, whether material or immaterial, do not restart the twenty-one (21) day period.  Executive agrees and acknowledges that if Executive chooses to sign this Agreement before twenty-one (21) days after Executive received it, that Executive has done so voluntarily.  Furthermore, Executive has a period of seven (7) days following the execution of this Agreement in which to revoke this Agreement.  Accordingly, this Agreement shall not become effective or enforceable (and none of the consideration set forth in Section 1 above shall be paid or recognized) until such seven (7) day revocation period has expired.

 

14.                               Counsel.  Executive acknowledges that Executive fully understands Executive’s right to discuss this Agreement with independent counsel of Executive’s choice, that Executive has carefully read and fully understands this entire Agreement and that Executive is voluntarily entering into this Agreement.

 

4

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement on this [      ] day of [                , 20    ], at San Diego, California.

 

	
EXECUTIVE:
    	
RECEPTOS:
    
	
 
    	
 
    
	
 
    	
RECEPTOS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
Christian Waage
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    	
Title:
    	
 
    

 

5ex10-1.htm

Exhibit 10.1

THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE, AND WILL BE OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF FEDERAL AND STATE LAW BY VIRTUE OF THE COMPANY'S INTENDED COMPLIANCE WITH SECTION 4(2) OF THE ACT, THE PROVISIONS OF REGULATION D PROMULGATED THEREUNDER, AND PARALLEL EXEMPTIONS UNDER STATE LAW.  THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY ANY REGULATORY AUTHORITY.  ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

Common Stock, $0.0001 Par Value Per Share

Common Stock Purchase Agreement

 

 

THIS COMMON STOCK PURCHASE AGREEMENT ("Agreement") is entered into between and among Greenscape Laboratories, Inc., a Wyoming corporation (the "Company"), and HD Retail Solutions, Inc., a corporation organized under the laws of the state of Nevada (the “Purchaser”), dated as of December 19, 2013.

RECITALS

A.           Subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to the Purchasers, and the Purchaser desires to subscribe for and purchase the number of shares of the Company’s Common Stock (the “Shares”) indicated below and on the signature page hereof.

B.           The Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act.

IN CONSIDERATION of the mutual covenants and promises set forth below and other good and valuable consideration, the receipt and adequacy of which the parties acknowledge by their signatures below, Purchaser hereby agrees to acquire, and the Company agrees to issue and sell, certain securities of the Company according to the terms and conditions set forth in this Agreement.

AGREEMENT

1.           Purchase of Securities.  Subject to the terms and conditions of this Agreement, Purchaser hereby agrees to acquire, and the Company agrees to sell, Thirty-six Million One Hundred Fifty-Two Thousand Seven Hundred Eighteen (36,152,718) shares of its Common Stock (the “Shares”).  The consideration paid for the Shares shall be One Million (1,000,000) shares of the Purchaser’s Series A Preferred Stock (the "Purchase Price"), which shall be payable in full by tendering one or more certificates, duly authorized and issued, in the name of the Company.

2.           Acceptance; Revocability.  This Agreement is irrevocable by Purchaser, but the Company may accept or reject it in whole or in part in its sole and absolute discretion and return the Purchase Price to the Purchaser without interest or deductions at any time prior to executing and delivering to the Purchaser a copy of this Agreement.  Upon acceptance by execution of this Agreement by the Company, which date shall constitute the closing date (the “Closing Date”) for the investor, however, the Company may not thereafter revoke this Agreement.

3.           Ownership of Preferred Stock by Company.  Purchaser acknowledges and agrees that if the Company accepts the Agreement, the Company shall become the owner of 1,000,000 shares of the Purchaser’s Series A Preferred Stock (the “HDRE Preferred Shares”), and shall have all rights as a shareholder of the HDRE Preferred Shares.

4.           Representations and Warranties of Purchaser.  To induce the Company's acceptance of this Agreement, Purchaser hereby represents and warrants to the Company and its agents and attorneys as follows:

  

1

  

4.1           Purchaser Status.  Purchaser either (A) is an “accredited investor” within the meaning of the Commission’s Rule 501 of Regulation D, as presently in effect, and as indicated below.  If the Purchaser resides in the United States, such Purchaser must be an Accredited Investor, and must indicate such status, by initialing the applicable paragraph (a) through (g) below, representing and warranting that the Purchaser is an "Accredited Investor" as defined in Regulation D under the Securities Act, because the Purchaser meets the requirements set forth in one or more of the enumerated categories.  The Purchaser has reviewed the Accredited Investor standards listed below and confirms it is an "Accredited Investor” as indicated below. Place your initials in the space provided in the beginning of each applicable paragraph thereby representing and warranting as to the applicability to the Purchaser of the initialed paragraph or paragraphs:

	
  

	
[

	
]

	
(a) any individual Purchaser whose net worth, or joint net worth with that person's spouse at the time of his purchase, exceeds $1,000,000 (including any individual participant of a Keogh Plan, IRA or IRA Rollover Purchaser) (Please Note: For purposes of category (1) you may include your spouse’s net worth, but may no longer include the fair market value of your primary residence.  This is a recent change to the law.  Please review carefully.);

 

	
  

	
[

	
]

	
(b) any individual Purchaser who had an income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those years and who reasonably expects an income in excess of the same income level in the current year (including any individual participant of a Keogh Plan, IRA or IRA Rollover Purchaser);

	
  

	
[

	
]

	
(c) any corporation or partnership not formed for the specific purpose of making an investment in the Common Stock, with total assets in excess of $5,000,000;

	
  

	
[

	
]

	
(d) any trust, which is not formed for the specific purpose of investing in the Common Stock, with total assets in excess of $5,000,000, whose purchase is directed by a sophisticated person, as such term is defined in Rule 506(b) of Regulation D under the Securities Act;

	
  

	
[

	
]

	
(e) any ERISA Plan if the investment decision is made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, insurance company, or registered investment adviser, or the Plan has total assets in excess of $5,000,000;

	
  

	
[

	
]

	
(f) any individual Purchaser who is an executive officer or director of the Company;

	
  

	
[

	
]

	
(g) any entity in which all of the equity owners are Accredited Investors under paragraphs (a), (b), (c) or (f) above or any other entity meeting required "Accredited Investor" standards under Rule 501 of Regulation D under the Securities Act and applicable State securities law criteria. IF THE PURCHASER IS AN ENTITY IN WHICH ALL OF THE EQUITY OWNERS ARE ACCREDITED INVESTORS, THE PURCHASER MUST PROVIDE A SUBSCRIPTION AGREEMENT FROM EACH OF ITS EQUITY OWNERS;

4.2           Authorization of Preferred Shares.  Purchaser represents and warrants that the Preferred Shares have been duly authorized and created, that all filings required by the State of Nevada to effectuate or reflect the creation of the Preferred Shares have been made and accepted by the State of Nevada, and that the Preferred Shares issued constitute all of the shares of Series A Preferred Stock of the Purchaser which have been authorized, and that no other shares of Series A Preferred Stock have been issued, sold, conveyed, or transferred in any way to any other person or holder.

  

2

  

4.3           Organization, Standing, Authorization.  If a corporation, limited liability company, or other entity, Purchaser is duly organized, validly existing, and in good standing under the laws of its State of organization, and has the requisite power and authority to enter into this Agreement, acquire the Shares and execute and deliver any documents or instruments in connection with this Agreement.  The execution and delivery of this Agreement, and all other documents and instruments executed by Purchaser in connection with any of the transactions contemplated by this Agreement have been duly authorized by all required action of Purchaser's members or managers.  The person executing, on Purchaser's behalf, this Agreement and any other documents or instruments executed by Purchaser in connection with this Agreement is duly authorized to do so.

4.4           Absence of Conflicts.  Purchaser represents and warrants that the execution and delivery of this Agreement and any other document or instrument executed in connection with this Agreement, and the consummation of the transactions contemplated thereby, and compliance with the requirements thereof, will not violate any law, rule, regulation, order, writ, judgment, injunction, decree or award binding on Purchaser, or the provision of any indenture, instrument or agreement to which Purchaser is a party or are subject, or by which Purchaser or any of its properties is bound, or conflict with or constitute a material default thereunder, or result in the creation or imposition of any lien pursuant to the terms of any such indenture, instrument or agreement, or constitute a breach of any fiduciary duty owed by either Purchaser to any third party, or require the approval of any third-party pursuant to any material contract, agreement, instrument, relationship or legal obligation to which Purchaser is subject or to which any of its properties, operations or management may be subject.

4.5           Sole Party in Interest.  Purchaser represents that it is the sole and true party in interest, and no other person or entity has or will have upon the issuance of the Shares any beneficial ownership interest in the Shares or any portion of the Shares, whether direct or indirect.

4.6           Knowledge and Experience.  Purchaser has been advised, to the Purchaser’s satisfaction and understanding, with respect to the advisability of an investment in the Company and the Shares.  Purchaser is experienced in evaluating and making speculative investments, and has the capacity to protect its interests in connection with the acquisition of the Shares.  Purchaser has such knowledge and experience in financial and business matters in general, and investments in the food and consumable product testing industry in particular, that Purchaser is capable of evaluating the merits and risks of Purchaser's investment in the Company.  Purchaser has been informed that an investment in the Company is speculative and has concluded that Purchaser's proposed investment is appropriate in light of its overall investment objectives and financial situation.

4.7           Investment Advisors.  Purchaser represents that no investment advisor or purchaser representative has been consulted or retained in connection with Purchaser's decision to invest in the Company.

4.8           Disclosure, Access to Information.  Purchaser confirms that it has received and thoroughly read and is familiar with and understands this Agreement, and all other information provided by the Company to date, and that all documents, records, books and other information pertaining to Purchaser's investment in the Company requested by Purchaser have been made available for inspection and copying and that there are no additional materials or documents that have been requested by Purchaser that have not been made available by the Company.  Purchaser further acknowledges it has had an opportunity to ask questions of and receive answers from the Company's representatives, and that any decision not to ask questions of the Company's representatives was a conscious decision on Purchaser’s part and reflects Purchaser's belief that no additional information is necessary in order to make an informed decision about investing in the Company.  Purchaser further acknowledges that it understands that the Company is not presently subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

4.9           Exclusive Reliance on this Agreement.  In making the decision to purchase the Shares, Purchaser has relied exclusively upon information included in this Agreement or incorporated herein by reference pursuant to Section 4.10, and investigations made by Purchaser, and not on any other representations, promises or information, whether written or verbal, by any person.

4.10           Accuracy of Unincorporated Documents and Other Unincorporated Materials.  To the extent Purchaser has received documents or other materials, other than as expressly incorporated herein by reference, Purchaser acknowledges the following with respect to such documents and materials:

  

3

  

(1)           Such documents and materials and any projections contained therein may be incomplete, may contain errors or misstatements, and do not purport to adequately describe the transactions contemplated by this Agreement or the status of the development of the Company's technology.  Purchaser agrees that such documents and materials cannot be relied upon in making a decision as to whether to purchase the Shares and acknowledges that there can be no assurance that any of the projections contained therein will be accomplished by the Company; and

(2)           Purchaser has been advised and fully understands that any summaries, projections, forecasts or estimates included in such documents and materials, including those relating to product development schedules and projections, possible revenues, income, profitability of the Company or an investment therein inherently involve uncertainties and may be affected by circumstances in the future which cannot be reasonably predicted and are beyond the control of the Company.  Further, the projections, forecasts and estimates are speculative and may be optimistic, and there can be no assurance that any of the projections, forecasts or estimates will be reached, or that the Company will successfully produce a commercially viable product or that the Company will realize any income or profits or that any dividends or distributions of profits will be paid on the Company's securities.

4.11           Residency.  If a corporation or other entity, Purchaser is organized under the laws of and has its principal place of business in the State of Nevada.

4.12           Advice of Counsel.  Purchaser understands the terms and conditions of this Agreement, has investigated all issues to Purchaser's satisfaction, has consulted with such of Purchaser's own legal counsel or other advisors as Purchaser deems necessary, and is not relying, and has not relied on the Company for an explanation of the terms or conditions of this Agreement or any document or instrument related to the transactions contemplated thereby.  Purchaser further acknowledges, understands, and agrees that, in arranging for the preparation of this Agreement and all other documents and materials related thereto, the Company has not attempted to procure, and has not procured, legal representation for Purchaser.

4.13  Accuracy of Representations and Information.  All representations made by Purchaser in this Agreement and all documents and instruments related to this Agreement, and all information provided by Purchaser to the Company concerning Purchaser and its respective financial positions is correct and complete as of the date hereof.  If there is any material change in such information before the actual issuance of the Shares, Purchaser immediately will provide such information to the Company.

4.14           No Representations.  None of the following have ever been represented, guaranteed, or warranted to Purchaser by the Company or any of its employees, agents, representatives or affiliates, or any broker or any other person, expressly or by implication:

(1)           The approximate or exact length of time that Purchaser will be required to remain as owner of the Shares;

(2)           The percentage of profit or amount of or type of consideration, profit or loss (including tax write-offs or other tax benefits) to be realized, if any, as a result of an investment in the Shares; or

(3)           The past performance or experience on the part of the Company or any affiliate or their associates, agents or employees, or of any other person as being indicative of future results of an investment in the Shares.

4.15           Federal Tax Matters.  Purchaser has reviewed and understands the federal income tax aspects of its purchase of the Shares, and has received such advice in this regard as Purchaser deems necessary from qualified sources such as attorneys, tax advisors or accountants, and is not relying on any representative or employee of the Company for such advice.

  

4

  

4.16           No Representations by Brokers or Finders.  Purchaser represents in making its decision to purchase the Shares, it is not relying on any representations, warranties, promises, or other inducements to purchase that were made by any broker, finder, or selling agent of the Company, and that the only representations, warranties, or other inducements to purchase are contained in the written materials provided by the Company to the Purchaser.

 

 

5.           Certain Risk Factors.  Purchaser has been informed about and fully understands that there are risks associated with an investment in the Company.  Such risks may include, but not necessarily be limited to:

-           the limited operating history of the Company;

-            the fact that there can be no assurance of the market’s acceptance of the services to be offered by the Company;

-            the fact that there can be no assurance that the Company will achieve profitability;

-           the limited experience of management in operating the Company; and

-           other risks relating to development stage companies with limited revenue and operating history. By signing below, the Purchaser acknowledges that he or she has reviewed and discussed the possible risks relating to an investment in the Company (including those set forth above), and further recognizes and acknowledges that an investment in the Company includes certain risks, not limited to those listed.

6.           Manner of Sale.  At no time was Purchaser presented with or solicited by or through any leaflet, public promotional meeting, television advertisement, or any other form of general solicitation or advertising.

7.           Restricted Securities.  Purchaser understands and acknowledges that resales of the Shares have not been registered under the Act, or any state securities laws, and the Shares will be issued in reliance upon certain exemptions from the registration requirements of those laws, and thus cannot be resold unless they are registered under the Act or unless the Company has first received an opinion of competent securities counsel that an exemption from registration is available for such resale.  With regard to the restrictions on resales of the Shares, Purchaser is aware (i) of the limitations and applicability of Securities and Exchange Commission Rule 144; (ii) that the Company will issue stop transfer orders to its transfer agent in the event of attempts to improperly transfer any such securities; and (iii) that a restrictive legend will be placed on the Shares and any security underlying or into which any of the Shares are or will be convertible, which legend will read substantially as follows:

THE SECURITIES REPRESENTED BY THIS NOTE HAVE BEEN ISSUED PURSUANT TO A CLAIM OF EXEMPTION FROM THE REGISTRATION OR QUALIFICATION PROVISIONS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND STATE SECURITIES LAWS AND THEREFORE HAVE NOT BEEN REGISTERED UNDER THE ACT OR UNDER THE SECURITIES LAWS OF ANY STATE.  THESE SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT COMPLIANCE WITH THE REGISTRATION OR QUALIFICATION PROVISIONS OF THE ACT OR APPLICABLE STATE LAWS, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS.  FURTHERMORE, THE COMPANY WILL INSTRUCT ITS STOCK TRANSFER AGENT NOT TO RECOGNIZE ANY SALE OF THESE SECURITIES UNLESS THE COMPANY HAS FIRST RECEIVED AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS SECURITIES COUNSEL, THAT AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS IS AVAILABLE.

8.           Indemnification.  Purchaser agrees to indemnify the Company, its officers employees and agents, and hold them harmless from and against any and all liability, damage, cost or expense, including attorney's fees, incurred on account or arising out of:

8.1           Any inaccuracy in the declarations, representations, and warranties by Purchaser set forth herein;

8.2           The disposition of the Shares or any portion thereof, by Purchaser contrary to the declarations, representations and warranties set forth herein and any restrictions on transfer that may be noted on the certificates representing such securities; and

8.3           Any action, suit or proceeding based upon (i) the claim that said declarations, representations, or warranties were inaccurate or misleading or otherwise cause for obtaining damages or redress from the Company; or (ii) the disposition of Shares, or any portion thereof.

  

5

  

9.           Conduct of Business; Interim Operations.  The Company covenants that, after execution of the Agreement, but before the Closing Date, the Company will use its best efforts to conduct its business and operations in a reasonable and professional manner and in accordance with past practices, to preserve its existing business organization and its relationships with its employees and other third parties, to preserve and protect its assets, and to conduct its business in compliance with all applicable laws and regulations.  Prior to the Closing Date, the Company will promptly inform Purchaser of any material developments or transactions involving the Company that arise after the date the parties execute this Agreement through the Closing Date.

10.           Representations and Warranties of the Company.  The Company hereby represents and warrants to Purchaser as follows:

10.1           Organization, Standing, Etc.  The Company is duly organized, validly existing, and in good standing under the laws of the State of Wyoming, and has the requisite power and authority to enter into and perform this Agreement and to execute and perform under the documents, instruments and agreements related to this Agreement.

10.2           Authorization.  The execution and delivery of this Agreement and the consummation of the transactions contemplated herein have been duly authorized by all required action of the Company.

11.           Confidentiality.  Purchaser acknowledges and agrees that the Company has provided it with certain information about the Company that is proprietary and confidential in connection with the consummation of the transactions contemplated by this Agreement (the "Confidential Information").  Purchaser covenants to preserve the confidentiality of the Confidential Information and to use the Confidential Information only for the purpose of determining to proceed with the transactions contemplated by this Agreement, and agree to do so for a period of five (5) years, except that information (i) in the public domain without violation of any confidentiality agreement, if known by the party receiving it before receipt, or (ii) received from a third party without violation of a non-disclosure obligation of that third party of the party delivering or disclosing information shall not be considered Confidential Information subject to this Section 11.

12.           Nondisclosure.  Except as required by applicable securities laws, rules and regulations, prior to the Closing Date, no press release or other announcement concerning the proposed transactions will be issued except by mutual consent of the parties.  This Agreement and all negotiations and discussions between the parties in connection with this Agreement shall be strictly confidential and will not be disclosed in any manner prior to the Closing Date, except to employees and agents of the parties on a need-to-know basis, as required by applicable law or regulations or as otherwise agreed by the parties.  After closing, disclosure shall be at the sole discretion of the Company.

13.           General Provisions.

13.1           Attorneys' Fees.  In the event of a default in the performance of this Agreement or any document or instrument executed in connection with this Agreement, the defaulting party, in addition to all other obligations of performance hereunder, shall pay reasonable attorneys' fees and costs incurred by the non-defaulting party to enforce performance or clarify the terms of this Agreement.

13.2           Choice of Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Wyoming, excluding its choice of law rules.

13.3           Counterparts.  This Agreement may be executed in one or more counterparts, each of which when so signed shall be deemed to be an original, and such counterparts together shall constitute one and the same instrument.

13.4           Entire Agreement.  This Agreement, and the Exhibits, Schedules and other attachments referred to herein (all of which are incorporated in this Agreement by reference) collectively set forth the entire agreement between the parties as to the subject matter hereof, supersede any and all prior or contemporaneous agreements or understandings of the parties relating to the subject matter of this Agreement, and may not be amended except by an instrument in writing signed by all of the parties to this Agreement.

13.5           Expenses.  The parties shall be responsible for and shall pay their own costs and expenses, including without limitation attorneys' fees and accountants' fees and expenses, in connection with the conduct of the due diligence inquiry, negotiation, execution and delivery of this Agreement and the instruments, documents and agreements executed in connection with this Agreement.

  

6

  

13.6           Headings.  The headings of the sections and paragraphs of this Agreement have been inserted for convenience of reference only and do not constitute a part of this Agreement.

13.7           Notices.  All notices or other communications provided for under this Agreement shall be in writing, and mailed, telecopied or delivered by hand delivery or by overnight courier service, to the parties at their respective addresses as indicated below or at such other address as the parties may designate in writing:

If to Purchaser, to it, him or them at:

HD Retail Solutions, Inc.

James R. J. Scheltema

1311 East La Rua Street

Pensacola, FL 32501

FAX: 850-912-8529

With a copy to:

Fax:                                                      

If to the Company, to it at:

 

 

Greenscape Laboratories, Inc.

1311 East La Rua St.

Pensacola, FL 32501

Fax: 850-912-8529

With a copy (which shall not constitute notice) to:

Small Cap Development, Inc.

707 E. Cervantes Street

Suite B, #109

Pensacola, FL 32501

All notices and communications shall be effective as follows:  When mailed, upon three (3) business days after deposit in the mail (postage prepaid); when telecopied, upon confirmed transmission of the telecopied notice; when hand delivered, upon delivery; and when sent by overnight courier, the next business day after deposit of the notice with the overnight courier.

13.8           Severability.  Should any one or more of the provisions of this Agreement be determined to be illegal or unenforceable, all other provisions of this Agreement shall be given effect separately from the provision or provisions determined to be illegal or unenforceable and shall not be affected thereby.

13.9           Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors, but shall not be assignable by Purchaser without the prior written consent of the Company.

  

7

  

13.10           Survival of Certain Representations, Warranties and Covenants Closing.  All warranties, representations, indemnities and agreements made in this Agreement by either party shall survive the date of this Agreement, the Closing Date, the consummation of the transactions contemplated by this Agreement, and the issuance by the Company of the Shares.

[SIGNATURE PAGES FOLLOW.]

  

8

  

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date indicated on the signature lines.

PURCHASER

HD RETAIL SOLUTIONS, INC.,

a Nevada corporation

	
By:

	
/s/ James R. J. Scheltema

	 	
Dated:  December 19, 2013

Name: James R. J. Scheltema                                                                                           

Title: President                                                                                                                  

Number of Shares Acquired:                           36,152,718                                                               

Consideration Paid:                                    1,000,000 Shares of HD Retail Solutions, Inc., Series A Preferred Stock  

 

 

ACCEPTED AND AGREED:

GREENSCAPE LABORATORIES, INC.

a Wyoming corporation

	
By:

	
/s/ James R. J. Scheltema

	 	
Dated: December 19, 2013

Name: James R. J. Scheltema                                                                                            

Title: President, CEO, CFO                                                                                               

  

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]